Gene · 4070
Papers3,230
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
481 to 500 of 3,230
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Contemporary management of metastatic urothelial carcinoma. | Investig Clin Urol | 2025 | 40897656 | PubTator, text mining | PubMed |
| TROP-2 overexpression in papillary renal cell carcinoma supports its potential as a therapeutic target for antibody-drug-conjugate therapy. | World J Urol | 2025 | 40888912 | PubTator, text mining | PubMed |
| Small cell lung cancer (SCLC): At the door of targeted therapies. | Biomol Biomed | 2025 | 40884462 | PubTator, text mining | PubMed |
| Multi-omic profiling of intraductal papillary neoplasms of the pancreas reveals distinct patterns and potential markers of progression. | Cancer Cell | 2025 | 40882635 | PubTator, text mining | PubMed |
| Adjuvant capecitabine in patients with triple-negative breast cancer after neoadjuvant chemotherapy. | ESMO Open | 2025 | 40882247 | PubTator, text mining | PubMed |
| Comprehensive Longitudinal Linear Mixed Modeling of CTCs Illuminates the Role of Trop2, EpCAM, and CD45 in CTC Clustering and Metastasis. | Cancers (Basel) | 2025 | 40867346 | PubTator, text mining | PubMed |
| Exploring TROP2 expression in oropharyngeal squamous cell carcinoma: Association with prognosis and tumor immune microenvironment composition. | Oral Oncol | 2025 | 40865331 | PubTator, text mining | PubMed |
| FDA Approval Summary: Datopotamab Deruxtecan-dlnk for Treatment of Patients with Unresectable or Metastatic, HR-Positive, HER2-Negative Breast Cancer. | Clin Cancer Res | 2025 | 40864501 | PubTator, text mining | PubMed |
| Recent Advances in the Management of EGFR-Mutated Advanced Non-Small Cell Lung Cancer-A Narrative Review. | Curr Oncol | 2025 | 40862817 | PubTator, text mining | PubMed |
| Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody-Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas. | Cancer Res Commun | 2025 | 40862536 | PubTator, text mining | PubMed |
| [Recent advances in antibody-drug conjugates for metastatic castration-resistant prostate cancer]. | Zhejiang Da Xue Xue Bao Yi Xue Ban | 2025 | 40859874 | PubTator, text mining | PubMed |
| SLFN11, far from being limited to responding to cancer DNA damage. | Clin Exp Med | 2025 | 40856812 | PubTator, text mining | PubMed |
| Antibody-drug conjugates for non-muscle invasive bladder cancer: current status and future development. | Curr Opin Urol | 2025 | 40855943 | PubTator, text mining | PubMed |
| Cellular cartography reveals mouse prostate organization and determinants of castration resistance. | Proc Natl Acad Sci U S A | 2025 | 40854129 | PubTator, text mining | PubMed |
| Pharmacotherapy for previously treated gastric cancer patients: current options and future developments. | Expert Rev Clin Pharmacol | 2025 | 40853034 | PubTator, text mining | PubMed |
| Unleashing NK cells for cancer immunotherapy in lung cancer: biologic challenges and clinical advances. | J Exp Clin Cancer Res | 2025 | 40849493 | PubTator, text mining | PubMed |
| Immunohistochemical examination of CD163 and TROP2 expression levels in ovarian endometriosis. | J Mol Histol | 2025 | 40844748 | PubTator, text mining | PubMed |
| Senkyunolide H reverses depression-induced breast cancer progression by regulating CXCR2. | Nat Prod Bioprospect | 2025 | 40839237 | PubTator, text mining | PubMed |
| Expression patterns of TROP2 and Nectin-4 in oropharyngeal squamous cell carcinoma in relation to HPV status: potential biomarkers for targeted therapy. | Ther Adv Med Oncol | 2025 | 40838147 | PubTator, text mining | PubMed |
| Causal associations between fibroblast growth factors and breast cancer: Evidence from 2-sample Mendelian randomization analysis. | Medicine (Baltimore) | 2025 | 40826783 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4070/papers?page=25